Pub Date : 2023-01-01DOI: 10.36468/pharmaceutical-sciences.1070
Defei Xian, Qin Tang
{"title":"Effect and Mechanism of Dexmedetomidine on Inhibiting Proliferation, Migration and Invasion of Ovarian Cancer Cell Strain SKOV3","authors":"Defei Xian, Qin Tang","doi":"10.36468/pharmaceutical-sciences.1070","DOIUrl":"https://doi.org/10.36468/pharmaceutical-sciences.1070","url":null,"abstract":"","PeriodicalId":13292,"journal":{"name":"Indian Journal of Pharmaceutical Sciences","volume":null,"pages":null},"PeriodicalIF":0.5,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70214928","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-01-01DOI: 10.36468/pharmaceutical-sciences.1139
E. Cho, Min-Sung Ko, C. H. Lee, Sul Lee, K. Hwang, So-Young Park
{"title":"Paeoniflorin Derivaties from Peony Roots Affecting Osteoblastic and Osteoclastic Differentiation","authors":"E. Cho, Min-Sung Ko, C. H. Lee, Sul Lee, K. Hwang, So-Young Park","doi":"10.36468/pharmaceutical-sciences.1139","DOIUrl":"https://doi.org/10.36468/pharmaceutical-sciences.1139","url":null,"abstract":"","PeriodicalId":13292,"journal":{"name":"Indian Journal of Pharmaceutical Sciences","volume":null,"pages":null},"PeriodicalIF":0.5,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69607419","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-01-01DOI: 10.36468/pharmaceutical-sciences.spl.691
Shan Huang, Xiaolei Wang, Lan Ma
: Effect
效果:
{"title":"Effect of Electrocardiogram Observation on Chemotherapy and Radiotherapy Combined with Trastuzumab in Breast Cancer Postoperative Patients","authors":"Shan Huang, Xiaolei Wang, Lan Ma","doi":"10.36468/pharmaceutical-sciences.spl.691","DOIUrl":"https://doi.org/10.36468/pharmaceutical-sciences.spl.691","url":null,"abstract":": Effect","PeriodicalId":13292,"journal":{"name":"Indian Journal of Pharmaceutical Sciences","volume":null,"pages":null},"PeriodicalIF":0.5,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69621296","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-01-01DOI: 10.36468/pharmaceutical-sciences.spl.676
Longqiang Guo, Degang Tao, Bing Chen, Hui Zhu, Fei Wang
We attempt to explore and study the effect of alendronate sodium combined with alpha-calciferol on chronic obstructive pulmonary disease patients with osteoporosis treatment and the changes of serum receptor activator for nuclear factor kappa B ligand and osteoprotegerin levels. We randomly selected 56 patients in the hospital from December 2021 to December 2022 as the study subjects. According to the time of admission, we divided them into two parts. 28 patients were given routine treatment as the control group and the other 28 patients were given alendronate sodium combined with alpha-calciferol as the observation group. Evaluate and compare both groups on the clinical efficacy rate and measure the serum receptor activator for nuclear factor kappa B ligand level and osteoprotegerin level after taking the fasting venous blood of the patients. The adverse reactions occurred during the treatment were counted and adverse reactions rate was calculated. The results showed that observation group had higher clinical control ratio and effective ratio than control group. In addition, observation group possessed higher clinical efficacy efficiency value of the patients than control group and the improvement was more obvious (p<0.05). In terms of serum level results, observation group had better data values of patients than control group. The serum receptor activator for nuclear factor kappa B ligand level, osteoprotegerin level, forced vital capacity 1 level and forced vital capacity 1/forced vital capacity values of patients in observation group were significantly improved than those in control group (p<0.05). In terms of adverse reaction evaluation, observation group during treatment had lower adverse reactions rate than control group (p<0.05). Alendronate sodium combined with alpha-calciferol can improve the clinical efficacy of chronic obstructive pulmonary disease and osteoporosis patients to a certain extent, and have a better effect on serum receptor activator for nuclear factor kappa B ligand, osteoprotegerin level and lung function.
{"title":"Effect of Alendronate Sodium Combined with Alpha-Calciferol on Chronic Obstructive Pulmonary Disease with Osteoporosis","authors":"Longqiang Guo, Degang Tao, Bing Chen, Hui Zhu, Fei Wang","doi":"10.36468/pharmaceutical-sciences.spl.676","DOIUrl":"https://doi.org/10.36468/pharmaceutical-sciences.spl.676","url":null,"abstract":"We attempt to explore and study the effect of alendronate sodium combined with alpha-calciferol on chronic obstructive pulmonary disease patients with osteoporosis treatment and the changes of serum receptor activator for nuclear factor kappa B ligand and osteoprotegerin levels. We randomly selected 56 patients in the hospital from December 2021 to December 2022 as the study subjects. According to the time of admission, we divided them into two parts. 28 patients were given routine treatment as the control group and the other 28 patients were given alendronate sodium combined with alpha-calciferol as the observation group. Evaluate and compare both groups on the clinical efficacy rate and measure the serum receptor activator for nuclear factor kappa B ligand level and osteoprotegerin level after taking the fasting venous blood of the patients. The adverse reactions occurred during the treatment were counted and adverse reactions rate was calculated. The results showed that observation group had higher clinical control ratio and effective ratio than control group. In addition, observation group possessed higher clinical efficacy efficiency value of the patients than control group and the improvement was more obvious (p<0.05). In terms of serum level results, observation group had better data values of patients than control group. The serum receptor activator for nuclear factor kappa B ligand level, osteoprotegerin level, forced vital capacity 1 level and forced vital capacity 1/forced vital capacity values of patients in observation group were significantly improved than those in control group (p<0.05). In terms of adverse reaction evaluation, observation group during treatment had lower adverse reactions rate than control group (p<0.05). Alendronate sodium combined with alpha-calciferol can improve the clinical efficacy of chronic obstructive pulmonary disease and osteoporosis patients to a certain extent, and have a better effect on serum receptor activator for nuclear factor kappa B ligand, osteoprotegerin level and lung function.","PeriodicalId":13292,"journal":{"name":"Indian Journal of Pharmaceutical Sciences","volume":null,"pages":null},"PeriodicalIF":0.5,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69621364","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-01-01DOI: 10.36468/pharmaceutical-sciences.spl.610
Bo Wen Wu, E. Y. Qiu, Weizhen Zeng, J. Chen, Z. Z. Li, A. Wu
{"title":"Impact of Complement C1qA and Complement C1qB on the Prognosis of Osteosarcoma","authors":"Bo Wen Wu, E. Y. Qiu, Weizhen Zeng, J. Chen, Z. Z. Li, A. Wu","doi":"10.36468/pharmaceutical-sciences.spl.610","DOIUrl":"https://doi.org/10.36468/pharmaceutical-sciences.spl.610","url":null,"abstract":"","PeriodicalId":13292,"journal":{"name":"Indian Journal of Pharmaceutical Sciences","volume":null,"pages":null},"PeriodicalIF":0.5,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69621551","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-01-01DOI: 10.36468/pharmaceutical-sciences.1175
Z. Lin, Yunsu Wang, Yanling Gao
To analyze that glaucocalyxin B can alleviate dyskinesia, inflammatory response and oxidative stress in Parkinson's disease model rats by activating the nuclear factor erythroid 2–related factor 2/heme oxygenase-1 pathway. 150 adults were divided into 5 groups, namely, the sham operation group (healthy mice), the Parkinson's group and the low-dose group (Parkinson+20 ng/ml) glaucocalyxin B), the medium-dose group (Parkinson+40 ng/ml glaucocalyxin B) and high-dose group (Parkinson+60 ng/ml glaucocalyxin B). The number of adjustment steps, the number of forepaw movements and the number of positive reactions in each group at 0 d have no difference; on the 3rd d in the Parkinson's group, dose group were reduced than in the sham operation group; on the 7th d, the number of steps in the Parkinson's group, and dose groups were reduced than the sham operation group. The tumor necrosis factor-alpha, interleukin-1 beta and interleukin-6 in the Parkinson's disease group, and dose groups were raised than those in the sham operation group, while these in the dose groups were reduced than in the Parkinson's group. The reactive oxidative stress concentration and myeloperoxidase activity of the Parkinson's group, dose group were raised than those of the sham operation group, while in the dose group were reduced than the Parkinson's group; superoxide dismutase activity level was reduced than the sham operation group. The levels of nuclear factor erythroid 2-related factor and heme oxygenase-1 in the Parkinson's group, dose groups were raised than those in the sham operation group, while in the dose groups were raised than those in the Parkinson's group. Further, in the low, medium and high dose groups increased with the increase of dose (p<0.05). Glaucocalyxin B can alleviate the dyskinesia of Parkinson's disease model rats and reduce the inflammatory response and oxidative stress response in rats, its relevant mechanism via activating the nuclear factor erythroid 2-related factor 2/heme oxygenase-1 pathway.
{"title":"Glaucocalyxin B Relieving Dyskinesia Inflammation and Oxidative Stress in Parkinson's Disease Model Rats by Activating the NRF2/HO-1 Pathway","authors":"Z. Lin, Yunsu Wang, Yanling Gao","doi":"10.36468/pharmaceutical-sciences.1175","DOIUrl":"https://doi.org/10.36468/pharmaceutical-sciences.1175","url":null,"abstract":"To analyze that glaucocalyxin B can alleviate dyskinesia, inflammatory response and oxidative stress in Parkinson's disease model rats by activating the nuclear factor erythroid 2–related factor 2/heme oxygenase-1 pathway. 150 adults were divided into 5 groups, namely, the sham operation group (healthy mice), the Parkinson's group and the low-dose group (Parkinson+20 ng/ml) glaucocalyxin B), the medium-dose group (Parkinson+40 ng/ml glaucocalyxin B) and high-dose group (Parkinson+60 ng/ml glaucocalyxin B). The number of adjustment steps, the number of forepaw movements and the number of positive reactions in each group at 0 d have no difference; on the 3rd d in the Parkinson's group, dose group were reduced than in the sham operation group; on the 7th d, the number of steps in the Parkinson's group, and dose groups were reduced than the sham operation group. The tumor necrosis factor-alpha, interleukin-1 beta and interleukin-6 in the Parkinson's disease group, and dose groups were raised than those in the sham operation group, while these in the dose groups were reduced than in the Parkinson's group. The reactive oxidative stress concentration and myeloperoxidase activity of the Parkinson's group, dose group were raised than those of the sham operation group, while in the dose group were reduced than the Parkinson's group; superoxide dismutase activity level was reduced than the sham operation group. The levels of nuclear factor erythroid 2-related factor and heme oxygenase-1 in the Parkinson's group, dose groups were raised than those in the sham operation group, while in the dose groups were raised than those in the Parkinson's group. Further, in the low, medium and high dose groups increased with the increase of dose (p<0.05). Glaucocalyxin B can alleviate the dyskinesia of Parkinson's disease model rats and reduce the inflammatory response and oxidative stress response in rats, its relevant mechanism via activating the nuclear factor erythroid 2-related factor 2/heme oxygenase-1 pathway.","PeriodicalId":13292,"journal":{"name":"Indian Journal of Pharmaceutical Sciences","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135360879","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-01-01DOI: 10.36468/pharmaceutical-sciences.spl.697
Jing Liu, C. Li, Wenjing Tang, S. Miao, Li Kang, S. Yu
{"title":"Sodium Propionate Treatment Improves Facial Pain and Changes of Intestinal Flora and its Metabolites Induced by Stimulation of Dura Inflammation Soup in Rats","authors":"Jing Liu, C. Li, Wenjing Tang, S. Miao, Li Kang, S. Yu","doi":"10.36468/pharmaceutical-sciences.spl.697","DOIUrl":"https://doi.org/10.36468/pharmaceutical-sciences.spl.697","url":null,"abstract":"","PeriodicalId":13292,"journal":{"name":"Indian Journal of Pharmaceutical Sciences","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135361564","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-01-01DOI: 10.36468/pharmaceutical-sciences.spl.700
Yichen Peng, D. Zheng, Yurong Zhang, Xianglin Chen, Jing Wang
{"title":"Establishment of Co-Culture Model of Primary Mature Adipocytes and Hepatocytes in Non-Alcoholic Fatty Liver Model Rats and its Effect on Hepatocyte Steatosis","authors":"Yichen Peng, D. Zheng, Yurong Zhang, Xianglin Chen, Jing Wang","doi":"10.36468/pharmaceutical-sciences.spl.700","DOIUrl":"https://doi.org/10.36468/pharmaceutical-sciences.spl.700","url":null,"abstract":"","PeriodicalId":13292,"journal":{"name":"Indian Journal of Pharmaceutical Sciences","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135361893","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-01-01DOI: 10.36468/pharmaceutical-sciences.spl.731
Jing Li, Di Zhang, Wenxiu Yao
The main objective of this study was to determine the effect, safety and intestinal microecology of amoxicillin-clavulanate potassium, ceftriaxone combined with pulmonary physical therapy on neonatal pneumonia. A total of 180 neonatal pneumonia patients in our hospital were studied and divided into research group (n=90) and control group (n=90). The control group was treated with amoxicillin-clavulanate potassium and ceftriaxone and the study group was treated with pulmonary physiotherapy on the basis of control group. The treatment cycle was 7 d. The two groups were compared with total response rate, symptom resolution time, lung function index, inflammatory factor index, adverse reactions and the number of major probiotics in the intestine. The total effective rate of the research group was significantly higher than that of the control group, the symptom disappearance time of the research group was shorter than that of the control group and the lung function index was better than that of the control group. The inflammatory factor index, the incidence of adverse reactions was lower than that of the control group and the main probiotics in the intestinal tract of the research group was more than that of the control group (p<0.05). For neonatal pneumonia, on the basis of amoxicillin-clavulanate potassium and ceftriaxone, supplemented with pulmonary physical therapy, the effect is better, the safety is high and it can improve the lung function level of patients, reduce the level of inflammatory factors and balance the gut microbiome.
{"title":"Effect and Safety of Amoxicillin-Clavulanate Potassium and Ceftriaxone Combined with Pulmonary Physical Therapy on Neonatal Pneumonia","authors":"Jing Li, Di Zhang, Wenxiu Yao","doi":"10.36468/pharmaceutical-sciences.spl.731","DOIUrl":"https://doi.org/10.36468/pharmaceutical-sciences.spl.731","url":null,"abstract":"The main objective of this study was to determine the effect, safety and intestinal microecology of amoxicillin-clavulanate potassium, ceftriaxone combined with pulmonary physical therapy on neonatal pneumonia. A total of 180 neonatal pneumonia patients in our hospital were studied and divided into research group (n=90) and control group (n=90). The control group was treated with amoxicillin-clavulanate potassium and ceftriaxone and the study group was treated with pulmonary physiotherapy on the basis of control group. The treatment cycle was 7 d. The two groups were compared with total response rate, symptom resolution time, lung function index, inflammatory factor index, adverse reactions and the number of major probiotics in the intestine. The total effective rate of the research group was significantly higher than that of the control group, the symptom disappearance time of the research group was shorter than that of the control group and the lung function index was better than that of the control group. The inflammatory factor index, the incidence of adverse reactions was lower than that of the control group and the main probiotics in the intestinal tract of the research group was more than that of the control group (p<0.05). For neonatal pneumonia, on the basis of amoxicillin-clavulanate potassium and ceftriaxone, supplemented with pulmonary physical therapy, the effect is better, the safety is high and it can improve the lung function level of patients, reduce the level of inflammatory factors and balance the gut microbiome.","PeriodicalId":13292,"journal":{"name":"Indian Journal of Pharmaceutical Sciences","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135595962","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-01-01DOI: 10.36468/pharmaceutical-sciences.1088
T. Chen, J. Liu, Z. Ding
Chen et al. : Integrated Analysis of Transcriptome in Interleukin-10 Interleukin 10 is one of the important cytokines of immune system inflammatory response in critical diseases such as sepsis. The regulation mechanism of its signal pathway and the mining of key members can provide targets for disease diagnosis and treatment. A large number of studies have analyzed the response of interleukin 10 treated cells by means of transcriptome and identified the members of signal pathway from differentially expressed genes. However, the conditions of different studies are different, resulting in great differences in results. It is necessary to integrate and analyze the inherent differentially expressed genes. In this study, we collected 17 sets of transcriptome experimental results, all of which were analyzed in the treatment of interleukin 10 in peripheral blood cells. Through meta-analysis of 4695 gene expression in all experiments, we screened 134 genes, which were statistically significant differentially expressed genes in the random effect model (p<0.005). These genes enrich biological pathways related to immunity and wounding. Among them, the p value of tissue inhibitor of metalloproteinase 1, leupaxin, FAM20A Golgi associated secretory pathway pseudo kinase and interferon induced protein 44 is ≤9.82e-06. In 17 groups of experiments, the difference trend is relatively consistent and more experiments have detected more than twice the difference. These genes are valuable biomarkers for interleukin 10 related diseases such as sepsis. At the same time, it is a key member of the relatively more conservative interleukin 10 signaling pathway under different conditions.
{"title":"Integrated Analysis of Transcriptome in Interleukin-10 Treated Peripheral Blood Cell Reveal Conservative Differential Expressed Genes","authors":"T. Chen, J. Liu, Z. Ding","doi":"10.36468/pharmaceutical-sciences.1088","DOIUrl":"https://doi.org/10.36468/pharmaceutical-sciences.1088","url":null,"abstract":"Chen et al. : Integrated Analysis of Transcriptome in Interleukin-10 Interleukin 10 is one of the important cytokines of immune system inflammatory response in critical diseases such as sepsis. The regulation mechanism of its signal pathway and the mining of key members can provide targets for disease diagnosis and treatment. A large number of studies have analyzed the response of interleukin 10 treated cells by means of transcriptome and identified the members of signal pathway from differentially expressed genes. However, the conditions of different studies are different, resulting in great differences in results. It is necessary to integrate and analyze the inherent differentially expressed genes. In this study, we collected 17 sets of transcriptome experimental results, all of which were analyzed in the treatment of interleukin 10 in peripheral blood cells. Through meta-analysis of 4695 gene expression in all experiments, we screened 134 genes, which were statistically significant differentially expressed genes in the random effect model (p<0.005). These genes enrich biological pathways related to immunity and wounding. Among them, the p value of tissue inhibitor of metalloproteinase 1, leupaxin, FAM20A Golgi associated secretory pathway pseudo kinase and interferon induced protein 44 is ≤9.82e-06. In 17 groups of experiments, the difference trend is relatively consistent and more experiments have detected more than twice the difference. These genes are valuable biomarkers for interleukin 10 related diseases such as sepsis. At the same time, it is a key member of the relatively more conservative interleukin 10 signaling pathway under different conditions.","PeriodicalId":13292,"journal":{"name":"Indian Journal of Pharmaceutical Sciences","volume":null,"pages":null},"PeriodicalIF":0.5,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69606362","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：